Key Insights

Highlights

Treatment Research

5 treatments under study, led by Rimactan 300 Mg Hörð Hylki

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed with results

Key Signals

1 with results

Data Visualizations

Phase Distribution

1Total
Phase 2 (1)

Trial Status

Unknown1

Clinical Trials (1)

Showing 1 of 1 trials
SYFb0d463f119574f7dbc26b05f56995491Phase 2Unknown

RANDOMIZED, CONTROLLED, OPEN, MULTICENTRIC CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A COMBINATION OF ANTI-TUBERCULOUS DRUGS BASED ON HIGH DOSE RIFAMPICIN, HIGH DOSE MOXIFLOXACIN AND LINEZOLID IN PATIENTS WITH BACILLIFEROUS PULMONARY TUBERCULOSIS (RML-TB).

Showing all 1 trials

Research Network

Common Treatments

  • Rimactan 300 Mg Hörð Hylki1
  • Rimstar Comprimidos Recubiertos Con Película1
  • Zyvoxid 600 Mg Filmtabletten1
  • Moxifloxacin Tillomed 400 Mg Film Coated Tablets1
  • Hidroxil B1b6b12 Comprimidos Recubiertos Con Película1

Activity Timeline